Ganitumab

Drug Profile

Ganitumab

Alternative Names: AMG-479

Latest Information Update: 15 Feb 2017

Price : $50

At a glance

  • Originator Amgen
  • Developer Amgen; Millennium; NantWorks; National Cancer Institute (USA); Takeda; Takeda Oncology; UCLAs Jonsson Comprehensive Cancer Center
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Insulin-like growth factor-I receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Ewing's sarcoma; Solid tumours
  • Phase Unknown Rhabdomyosarcoma
  • No development reported Breast cancer; Colorectal cancer; Sarcoma; Small cell lung cancer
  • Discontinued Non-small cell lung cancer; Pancreatic cancer; Prostate cancer

Most Recent Events

  • 10 Feb 2017 National Cancer Institute plans a phase I/II trial for Rhabdomyosarcoma in USA (NCT03041701)
  • 02 Feb 2017 Investigation in Rhabdomyosarcoma in USA (unspecified route) before February 2017 (NCT03041701)
  • 23 Jan 2017 Clinical trials (expanded access programme) in Ewing's Sarcoma (Monotherapy, Second-line therapy or greater, Metastatic disease) in USA (IV) before January 2017 (NCT03029481)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top